EpiAxis is pioneering next-generation LSD1 inhibitors to unlock powerful, durable treatments for patients with aggressive solid tumours, transforming resistance into responsiveness, and science into hope.
EpiAxis Therapeutics is developing novel reversible macrocyclic peptide inhibitors of LSD1, an enzyme that drives treatment resistance in advanced cancers. By targeting LSD1’s role in the neuroendocrine transition, our approach aims to extend the effectiveness of existing therapies in prostate, colorectal, and small cell lung cancers.
With strong science, a lean leadership team, and guidance from world-class advisors, we are advancing toward a first-in-human study by mid-2026.
In preclinical prostate cancer models, EpiAxis peptides have delivered significant tumour reduction at lower doses, supporting advancement toward the clinic. Additional efficacy and PK/PD studies are underway to finalise candidate selection.
US$500k raise to complete optimisation and select lead candidate & indication by Q2 2026
~US $5m institutional raise to fund GLP tox, CMC, and an Australia‑based Phase I healthy volunteer study
First‑in‑human readiness and near‑term clinical data path
Target value inflection with acquisition/licensing potential
EpiAxis is pioneering reversible cyclic peptide inhibitors of LSD1, designed to overcome the limitations of first-generation approaches and extend the impact of existing cancer therapies. Our work is guided by a clear scientific focus, a differentiated mode of action, and global collaborations.
Targeting LSD1, a validated cancer driver implicated in both blood and solid tumours.
Tackling treatment resistance by preventing the neuroendocrine transition that allows cancers to evade current drugs.
Advancing therapies in cancers with high unmet need, including prostate, small cell lung, and colorectal.
LSD1 biology: Essential for tumour growth but also critical in normal platelet formation.
Irreversible inhibitors: Switch off all LSD1 biology (“sledgehammer approach”), leading to on-target toxicities such as dangerously low platelet counts.
Reversible binding: Our peptides allow tighter control of LSD1 activity, aiming to minimise toxicity while enabling broader use and combination potential.
Reversible cyclic peptide inhibitors that balance potency with selectivity.
Demonstrated efficacy in preclinical prostate cancer models, showing significant tumour reduction.
Differentiated discovery platform, DNA-encoded library (DEL) screening of >100 billion molecules, generating multiple novel peptide families with ring-fenced IP.
Clear path to clinic: Candidate and lead indication selection by Q2 2026, with a Phase I healthy volunteer study planned thereafter.
At EpiAxis, our mission is to change the course of advanced cancers by targeting the epigenetic regulator LSD1. We are developing next-generation therapies designed to overcome resistance, extend treatment possibilities, and bring new hope to patients facing aggressive solid tumours.
Through a relentless focus on high-quality translational science, strategic collaborations, and a clear clinical pathway, we aim to deliver breakthrough medicines that improve outcomes for patients and create lasting value for our partners and shareholders.